Skip to content

Atrial Fibrillation and Neuropathic Pain After Thoracotomy and Continuous Application of Magnesium Sulphate.

CompletedNot applicableNCT02008747
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Atrial fibrillation and chronic neuropathic pain are adverse events occurring after posterolateral thoracotomy for lung resection. The continuous application of magnesium sulphate may have a prophylactic effect. The investigators record the incidence of atrial fibrillation during a seven day period after thoracotomy as well as the incidence of chronic neuropathic pain during a three months period, comparing one group with a continuous application of magnesium sulphate against one group without magnesium sulphate.

Study details

Official title
Effects of Prophylactic Administration of Magnesium Sulfate on the Incidence of Atrial Fibrillation and Chronic Neuropathic Pain After Thoracotomy for Lung Resection.
Conditions
Interventions
  • Drug: Magnesium sulphate
Sponsor
Dr. Horst Schmidt Klinik GmbH
Start date
2011-01
Primary completion
2012-02
Sex
All
Age range
from 18 Years
Results posted
No results posted in this snapshot
Countries
Germany
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 18 years or older * posterolateral thoracotomy for lung parenchyma resection * informed consent Exclusion Criteria: * hypersensitivity for magnesium sulphate * pre-existing atrial fibrillation * participation in another trial * pregnancy or breastfeeding

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02008747